Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction

Detalhes bibliográficos
Autor(a) principal: Fuellhase, Claudius
Data de Publicação: 2010
Outros Autores: Soler, Roberto [UNIFESP], Gratzke, Christian, Brodsky, Marina, Christ, George J., Andersson, Karl-Erik
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNIFESP
dARK ID: ark:/48912/00130000103p4
DOI: 10.1111/j.1464-410X.2009.09008.x
Texto Completo: http://dx.doi.org/10.1111/j.1464-410X.2009.09008.x
http://repositorio.unifesp.br/handle/11600/32645
Resumo: OBJECTIVETo evaluate the urodynamic effects of fesoterodine, a new antimuscarinic agent, alone and combined with doxazosin, in a rat model of partial urethral obstruction (PUO), as 35-83% of men with bladder outlet obstruction (BOO) secondary to benign prostatic hyperplasia (BPH) have overactive bladder (OAB) syndrome, and as the combination of alpha(1)-adrenoceptor- and muscarinic-receptor antagonists has been proposed to be beneficial for these patients.MATERIALS and METHODSThirty-seven male Sprague-Dawley rats (250 g) had surgically induced PUO; 2 weeks later they were evaluated by cystometry with no anaesthesia or any restraint. After a 1-h period either 5-hydroxymethyl tolterodine (5-HMT, the active metabolite of fesoterodine, previously known as SPM 7605), doxazosin or a combination of both, was given intravenously (0.1 mg/kg body weight), and cystometry was continued for another 45 min. Fifteen healthy, age-matched rats served as a control.RESULTSAt 2 weeks after surgery the obstructed rats had an greater bladder weight, threshold pressure (TP) and micturition frequency (MF), and lower bladder capacity (BCap) and micturition volume (MV) than the controls. 5-HMT did not cause urinary retention in obstructed rats, but decreased TP, maximum pressure (MP), spontaneous bladder activity (SA) and, paradoxically, increased MF. Doxazosin alone decreased TP, MP, MF and increased BCap and MV. 5-HMT and doxazosin together did not depress the ability to empty the bladder, and showed decreased TP, MP and SA.CONCLUSIONS5-HMT, alone and in combination, did not impair the voiding ability in obstructed rats. Doxazosin counteracted some of the 'negative' effects of 5-HMT in this model (increase of MF) and did not attenuate the 'positive' effects (decrease of bladder SA). in this model, the combination of 5-HMT and doxazosin appeared to be urodynamically safe and well tolerated.
id UFSP_1b6fe037969dd97302eef5ea81ddd0ad
oai_identifier_str oai:repositorio.unifesp.br/:11600/32645
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstructionfesoterodinedoxazosinbladder outlet obstructionoveractive bladderantimuscarinic agentsalpha-adrenergic blockersOBJECTIVETo evaluate the urodynamic effects of fesoterodine, a new antimuscarinic agent, alone and combined with doxazosin, in a rat model of partial urethral obstruction (PUO), as 35-83% of men with bladder outlet obstruction (BOO) secondary to benign prostatic hyperplasia (BPH) have overactive bladder (OAB) syndrome, and as the combination of alpha(1)-adrenoceptor- and muscarinic-receptor antagonists has been proposed to be beneficial for these patients.MATERIALS and METHODSThirty-seven male Sprague-Dawley rats (250 g) had surgically induced PUO; 2 weeks later they were evaluated by cystometry with no anaesthesia or any restraint. After a 1-h period either 5-hydroxymethyl tolterodine (5-HMT, the active metabolite of fesoterodine, previously known as SPM 7605), doxazosin or a combination of both, was given intravenously (0.1 mg/kg body weight), and cystometry was continued for another 45 min. Fifteen healthy, age-matched rats served as a control.RESULTSAt 2 weeks after surgery the obstructed rats had an greater bladder weight, threshold pressure (TP) and micturition frequency (MF), and lower bladder capacity (BCap) and micturition volume (MV) than the controls. 5-HMT did not cause urinary retention in obstructed rats, but decreased TP, maximum pressure (MP), spontaneous bladder activity (SA) and, paradoxically, increased MF. Doxazosin alone decreased TP, MP, MF and increased BCap and MV. 5-HMT and doxazosin together did not depress the ability to empty the bladder, and showed decreased TP, MP and SA.CONCLUSIONS5-HMT, alone and in combination, did not impair the voiding ability in obstructed rats. Doxazosin counteracted some of the 'negative' effects of 5-HMT in this model (increase of MF) and did not attenuate the 'positive' effects (decrease of bladder SA). in this model, the combination of 5-HMT and doxazosin appeared to be urodynamically safe and well tolerated.Wake Forest Univ, Wake Forest Inst Regenerat Med, Winston Salem, NC 27157 USAPfizer Inc, New York, NY USALudwig Maximilians Univ Munchen, Univ Hosp Grosshadern, Dept Urol, Munich, GermanyUniversidade Federal de São Paulo, Div Urol, São Paulo, BrazilUniversidade Federal de São Paulo, Div Urol, São Paulo, BrazilWeb of SciencePfizer IncWiley-BlackwellWake Forest UnivPfizer IncLudwig Maximilians Univ MunchenUniversidade Federal de São Paulo (UNIFESP)Fuellhase, ClaudiusSoler, Roberto [UNIFESP]Gratzke, ChristianBrodsky, MarinaChrist, George J.Andersson, Karl-Erik2016-01-24T13:59:49Z2016-01-24T13:59:49Z2010-07-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion287-293http://dx.doi.org/10.1111/j.1464-410X.2009.09008.xBju International. Malden: Wiley-Blackwell, v. 106, n. 2, p. 287-293, 2010.10.1111/j.1464-410X.2009.09008.x1464-4096http://repositorio.unifesp.br/handle/11600/32645WOS:000278913200025ark:/48912/00130000103p4engBju Internationalinfo:eu-repo/semantics/openAccesshttp://olabout.wiley.com/WileyCDA/Section/id-406071.htmlreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2016-01-24T11:59:49Zoai:repositorio.unifesp.br/:11600/32645Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-12-11T20:46:39.735314Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.none.fl_str_mv Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction
title Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction
spellingShingle Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction
Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction
Fuellhase, Claudius
fesoterodine
doxazosin
bladder outlet obstruction
overactive bladder
antimuscarinic agents
alpha-adrenergic blockers
Fuellhase, Claudius
fesoterodine
doxazosin
bladder outlet obstruction
overactive bladder
antimuscarinic agents
alpha-adrenergic blockers
title_short Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction
title_full Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction
title_fullStr Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction
Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction
title_full_unstemmed Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction
Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction
title_sort Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction
author Fuellhase, Claudius
author_facet Fuellhase, Claudius
Fuellhase, Claudius
Soler, Roberto [UNIFESP]
Gratzke, Christian
Brodsky, Marina
Christ, George J.
Andersson, Karl-Erik
Soler, Roberto [UNIFESP]
Gratzke, Christian
Brodsky, Marina
Christ, George J.
Andersson, Karl-Erik
author_role author
author2 Soler, Roberto [UNIFESP]
Gratzke, Christian
Brodsky, Marina
Christ, George J.
Andersson, Karl-Erik
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Wake Forest Univ
Pfizer Inc
Ludwig Maximilians Univ Munchen
Universidade Federal de São Paulo (UNIFESP)
dc.contributor.author.fl_str_mv Fuellhase, Claudius
Soler, Roberto [UNIFESP]
Gratzke, Christian
Brodsky, Marina
Christ, George J.
Andersson, Karl-Erik
dc.subject.por.fl_str_mv fesoterodine
doxazosin
bladder outlet obstruction
overactive bladder
antimuscarinic agents
alpha-adrenergic blockers
topic fesoterodine
doxazosin
bladder outlet obstruction
overactive bladder
antimuscarinic agents
alpha-adrenergic blockers
description OBJECTIVETo evaluate the urodynamic effects of fesoterodine, a new antimuscarinic agent, alone and combined with doxazosin, in a rat model of partial urethral obstruction (PUO), as 35-83% of men with bladder outlet obstruction (BOO) secondary to benign prostatic hyperplasia (BPH) have overactive bladder (OAB) syndrome, and as the combination of alpha(1)-adrenoceptor- and muscarinic-receptor antagonists has been proposed to be beneficial for these patients.MATERIALS and METHODSThirty-seven male Sprague-Dawley rats (250 g) had surgically induced PUO; 2 weeks later they were evaluated by cystometry with no anaesthesia or any restraint. After a 1-h period either 5-hydroxymethyl tolterodine (5-HMT, the active metabolite of fesoterodine, previously known as SPM 7605), doxazosin or a combination of both, was given intravenously (0.1 mg/kg body weight), and cystometry was continued for another 45 min. Fifteen healthy, age-matched rats served as a control.RESULTSAt 2 weeks after surgery the obstructed rats had an greater bladder weight, threshold pressure (TP) and micturition frequency (MF), and lower bladder capacity (BCap) and micturition volume (MV) than the controls. 5-HMT did not cause urinary retention in obstructed rats, but decreased TP, maximum pressure (MP), spontaneous bladder activity (SA) and, paradoxically, increased MF. Doxazosin alone decreased TP, MP, MF and increased BCap and MV. 5-HMT and doxazosin together did not depress the ability to empty the bladder, and showed decreased TP, MP and SA.CONCLUSIONS5-HMT, alone and in combination, did not impair the voiding ability in obstructed rats. Doxazosin counteracted some of the 'negative' effects of 5-HMT in this model (increase of MF) and did not attenuate the 'positive' effects (decrease of bladder SA). in this model, the combination of 5-HMT and doxazosin appeared to be urodynamically safe and well tolerated.
publishDate 2010
dc.date.none.fl_str_mv 2010-07-01
2016-01-24T13:59:49Z
2016-01-24T13:59:49Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1111/j.1464-410X.2009.09008.x
Bju International. Malden: Wiley-Blackwell, v. 106, n. 2, p. 287-293, 2010.
10.1111/j.1464-410X.2009.09008.x
1464-4096
http://repositorio.unifesp.br/handle/11600/32645
WOS:000278913200025
dc.identifier.dark.fl_str_mv ark:/48912/00130000103p4
url http://dx.doi.org/10.1111/j.1464-410X.2009.09008.x
http://repositorio.unifesp.br/handle/11600/32645
identifier_str_mv Bju International. Malden: Wiley-Blackwell, v. 106, n. 2, p. 287-293, 2010.
10.1111/j.1464-410X.2009.09008.x
1464-4096
WOS:000278913200025
ark:/48912/00130000103p4
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Bju International
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
http://olabout.wiley.com/WileyCDA/Section/id-406071.html
eu_rights_str_mv openAccess
rights_invalid_str_mv http://olabout.wiley.com/WileyCDA/Section/id-406071.html
dc.format.none.fl_str_mv 287-293
dc.publisher.none.fl_str_mv Wiley-Blackwell
publisher.none.fl_str_mv Wiley-Blackwell
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv biblioteca.csp@unifesp.br
_version_ 1822250897532518400
dc.identifier.doi.none.fl_str_mv 10.1111/j.1464-410X.2009.09008.x